SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

ChatGPT vs Claude: Scoping Review with ☸️SAIMSARA

Digital Health icon

Digital Health

Issue 3, Volume 1, 2026

DOI: 10.62487/saimsarafe254f1e

Editorial note
• Last update: 2026-05-17 21:52:28
What is this paper about
ChatGPT vs Claude is not a contest with one winner: the evidence map shows that model performance flips by task, version, modality, and risk level across medicine, education, coding, safety, and research workflows. The full evidence map turns scattered benchmark studies into a practical guide for choosing the right model, identifying where human oversight is essential, and understanding where each system actually performs best.
Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Evidence preview · Did you know?
Realistic hospital medication-safety scene with clinicians checking pediatric dosage support from two AI systems.

AI can look useful in narrow care tasks

Did you know? Claude-3.0 and ChatGPT-4o achieved 100% accuracy in pediatric medication dosage calculations and were faster than nurses.

This is a strong practical signal, but it applies to a narrow task — not autonomous clinical care.

Realistic medical AI comparison scene with radiology workstations and two different diagnostic workflows.

The winner can flip inside medicine

Did you know? Claude beat ChatGPT-4o in stroke DWI interpretation, 67.2% vs 32.7%, while ChatGPT-4o beat Claude in MRI sequence classification, 97.7% vs 73.1%.

The real question is not which model is best, but which model fits the exact task, modality, and endpoint.

Realistic AI safety and cybersecurity governance scene with clinicians and engineers reviewing model-risk alerts.

Safety rankings can collapse

Did you know? Claude had lower jailbreak success than ChatGPT in CySecBench, 17% vs 65%, but a later role-play attack found both systems above 94% failure.

Governance cannot rely on one benchmark because safeguards change by version, prompt style, and attack type.

Swipe sideways on mobile · full evidence map opens after unlock
Abstract: To synthesize original comparative evidence evaluating ChatGPT and Claude across clinical, educational, technical, safety, linguistic, and research-use settings, with emphasis on whether one model shows a consistent advantage or whether performance is task- and context-dependent. The review uses 156 references and builds its evidence map from 519 original studies with 6,412,048 total participants/sample observations (topic-deduplicated ΣN). This scoping review suggests that the “ChatGPT versus Claude” question has no single winner, and that comparative performance is consistently task-, version-, modality-, and endpoint-specific. Claude tended to show advantages in structured reasoning, safety-oriented behavior, and selected diagnostic tasks such as acute ischemic stroke imaging and oncology board questions, while ChatGPT more often led in readability, speed, and patient-facing outputs such as gestational diabetes information. Both systems shared important weaknesses, including hallucinated references, jailbreak vulnerability, and clinically insufficient performance in high-stakes settings. Practically, this indicates that model choice should be matched to the specific task and that human oversight remains essential before deployment. Future research should prioritize matched, version-stamped benchmarking with standardized prompts, multimodal endpoints, and safety stress testing to clarify where each model offers durable advantages.

Keywords: ChatGPT; Claude; Large language models; Comparative evaluation; Artificial intelligence; Diagnostic accuracy; Medical question answering; Model bias; Code generation; Patient education

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (156)